- Home
- WIA vs IPHA Comparison
WIA vs IPHA Comparison
Compare WIA & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- IPHA
- Stock Information
- Founded
- WIA 2003
- IPHA 1999
- Country
- WIA United States
- IPHA France
- Employees
- WIA N/A
- IPHA N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- WIA Finance
- IPHA Health Care
- Exchange
- WIA Nasdaq
- IPHA Nasdaq
- Market Cap
- WIA 186.8M
- IPHA 150.9M
- IPO Year
- WIA N/A
- IPHA 2019
- Fundamental
- Price
- WIA $8.22
- IPHA $1.95
- Analyst Decision
- WIA
- IPHA Strong Buy
- Analyst Count
- WIA 0
- IPHA 1
- Target Price
- WIA N/A
- IPHA $11.50
- AVG Volume (30 Days)
- WIA 39.2K
- IPHA 50.9K
- Earning Date
- WIA 01-01-0001
- IPHA 03-20-2025
- Dividend Yield
- WIA 12.29%
- IPHA N/A
- EPS Growth
- WIA N/A
- IPHA N/A
- EPS
- WIA N/A
- IPHA N/A
- Revenue
- WIA N/A
- IPHA $36,202,722.00
- Revenue This Year
- WIA N/A
- IPHA N/A
- Revenue Next Year
- WIA N/A
- IPHA $101.65
- P/E Ratio
- WIA N/A
- IPHA N/A
- Revenue Growth
- WIA N/A
- IPHA N/A
- 52 Week Low
- WIA $7.56
- IPHA $1.29
- 52 Week High
- WIA $8.91
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- WIA 59.46
- IPHA 56.50
- Support Level
- WIA $8.09
- IPHA $1.72
- Resistance Level
- WIA $8.21
- IPHA $1.92
- Average True Range (ATR)
- WIA 0.09
- IPHA 0.11
- MACD
- WIA 0.02
- IPHA 0.02
- Stochastic Oscillator
- WIA 73.33
- IPHA 89.74
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.